{"id":"https://openalex.org/W7225823798","doi":"https://doi.org/10.3389/fddsv.2026.1918390","title":"Integrated virtual screening in discovering dual EGFR and Src inhibitor candidates","display_name":"Integrated virtual screening in discovering dual EGFR and Src inhibitor candidates","publication_year":2026,"publication_date":"2026-11-11","ids":{"openalex":"https://openalex.org/W7225823798","doi":"https://doi.org/10.3389/fddsv.2026.1918390"},"language":"en","primary_location":{"id":"doi:10.3389/fddsv.2026.1918390","doi":"https://doi.org/10.3389/fddsv.2026.1918390","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fddsv.2026.1918390","pdf_url":"https://www.frontiersin.org/journals/drug-discovery/articles/10.3389/fddsv.2026.1918390/pdf","source":{"id":"https://openalex.org/S4210199683","display_name":"Frontiers in Drug Discovery","issn_l":"2674-0338","issn":["2674-0338"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Drug Discovery","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/drug-discovery/articles/10.3389/fddsv.2026.1918390/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5088284831","display_name":"Junaidin Junaidin","orcid":"https://orcid.org/0000-0001-5922-8550","observed_orcids":["https://orcid.org/0000-0001-5922-8550"]},"institutions":[{"id":"https://openalex.org/I134635517","display_name":"Bandung Institute of Technology","ror":"https://ror.org/00apj8t60","country_code":"ID","type":"education","lineage":["https://openalex.org/I134635517"]},{"id":"https://openalex.org/I4404532933","display_name":"Universitas Teknologi Bandung","ror":"https://ror.org/00rj2jz45","country_code":"ID","type":"education","lineage":["https://openalex.org/I4404532933"]}],"countries":["ID"],"is_corresponding":false,"raw_author_name":"Junaidin Junaidin","raw_affiliation_strings":["Department of Pharmacochemistry, School of Pharmacy, Bandung Institute of Technology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacochemistry, School of Pharmacy, Bandung Institute of Technology","institution_ids":["https://openalex.org/I134635517","https://openalex.org/I4404532933"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051658385","display_name":"Fransiska Kurniawan","orcid":"https://orcid.org/0000-0003-0885-1777","observed_orcids":["https://orcid.org/0000-0003-0885-1777"]},"institutions":[{"id":"https://openalex.org/I134635517","display_name":"Bandung Institute of Technology","ror":"https://ror.org/00apj8t60","country_code":"ID","type":"education","lineage":["https://openalex.org/I134635517"]},{"id":"https://openalex.org/I4404532933","display_name":"Universitas Teknologi Bandung","ror":"https://ror.org/00rj2jz45","country_code":"ID","type":"education","lineage":["https://openalex.org/I4404532933"]}],"countries":["ID"],"is_corresponding":false,"raw_author_name":"Fransiska Kurniawan","raw_affiliation_strings":["Department of Pharmacochemistry, School of Pharmacy, Bandung Institute of Technology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacochemistry, School of Pharmacy, Bandung Institute of Technology","institution_ids":["https://openalex.org/I134635517","https://openalex.org/I4404532933"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5009638987","display_name":"Daryono Hadi Tjahjono","orcid":"https://orcid.org/0000-0002-9675-0134","observed_orcids":["https://orcid.org/0000-0002-9675-0134"]},"institutions":[{"id":"https://openalex.org/I134635517","display_name":"Bandung Institute of Technology","ror":"https://ror.org/00apj8t60","country_code":"ID","type":"education","lineage":["https://openalex.org/I134635517"]},{"id":"https://openalex.org/I4404532933","display_name":"Universitas Teknologi Bandung","ror":"https://ror.org/00rj2jz45","country_code":"ID","type":"education","lineage":["https://openalex.org/I4404532933"]}],"countries":["ID"],"is_corresponding":true,"raw_author_name":"Daryono Hadi Tjahjono","raw_affiliation_strings":["Department of Pharmacochemistry, School of Pharmacy, Bandung Institute of Technology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacochemistry, School of Pharmacy, Bandung Institute of Technology","institution_ids":["https://openalex.org/I134635517","https://openalex.org/I4404532933"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5009638987"],"corresponding_institution_ids":["https://openalex.org/I134635517","https://openalex.org/I4404532933"],"apc_list":{"value":1950,"currency":"CHF","value_usd":2353},"apc_paid":{"value":1950,"currency":"CHF","value_usd":2353},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"6","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T14099","display_name":"Synthesis and Characterization of Heterocyclic Compounds","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C56173144","wikidata":"https://www.wikidata.org/wiki/Q1539893","display_name":"Pharmacophore","level":2,"score":0.8482999801635742},{"id":"https://openalex.org/C108636557","wikidata":"https://www.wikidata.org/wiki/Q21109354","display_name":"Proto-oncogene tyrosine-protein kinase Src","level":3,"score":0.7558000087738037},{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.7421000003814697},{"id":"https://openalex.org/C103697762","wikidata":"https://www.wikidata.org/wiki/Q4112105","display_name":"Virtual screening","level":3,"score":0.7409999966621399},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.7315999865531921},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.5917999744415283},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.5424000024795532},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.4993000030517578},{"id":"https://openalex.org/C41685203","wikidata":"https://www.wikidata.org/wiki/Q1974042","display_name":"Docking (animal)","level":2,"score":0.4984000027179718},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4966999888420105},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.40299999713897705},{"id":"https://openalex.org/C2909867262","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Protein-Tyrosine Kinases","level":4,"score":0.33970001339912415},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.32199999690055847},{"id":"https://openalex.org/C74187038","wikidata":"https://www.wikidata.org/wiki/Q1418791","display_name":"Drug discovery","level":2,"score":0.3158999979496002},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3073999881744385},{"id":"https://openalex.org/C107824862","wikidata":"https://www.wikidata.org/wiki/Q616005","display_name":"Binding site","level":2,"score":0.2939000129699707},{"id":"https://openalex.org/C2775905019","wikidata":"https://www.wikidata.org/wiki/Q192572","display_name":"In silico","level":3,"score":0.2888000011444092},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.2825999855995178},{"id":"https://openalex.org/C2780586478","wikidata":"https://www.wikidata.org/wiki/Q4688818","display_name":"Afatinib","level":5,"score":0.28220000863075256},{"id":"https://openalex.org/C2909325608","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib Hydrochloride","level":5,"score":0.28060001134872437},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.2766000032424927},{"id":"https://openalex.org/C51639874","wikidata":"https://www.wikidata.org/wiki/Q167149","display_name":"Plasma protein binding","level":2,"score":0.2761000096797943},{"id":"https://openalex.org/C3018795828","wikidata":"https://www.wikidata.org/wiki/Q899107","display_name":"Binding affinities","level":3,"score":0.27140000462532043},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.26440000534057617}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.3389/fddsv.2026.1918390","doi":"https://doi.org/10.3389/fddsv.2026.1918390","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fddsv.2026.1918390","pdf_url":"https://www.frontiersin.org/journals/drug-discovery/articles/10.3389/fddsv.2026.1918390/pdf","source":{"id":"https://openalex.org/S4210199683","display_name":"Frontiers in Drug Discovery","issn_l":"2674-0338","issn":["2674-0338"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Drug Discovery","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.3389/fddsv.2026.1918390","doi":"https://doi.org/10.3389/fddsv.2026.1918390","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fddsv.2026.1918390","pdf_url":"https://www.frontiersin.org/journals/drug-discovery/articles/10.3389/fddsv.2026.1918390/pdf","source":{"id":"https://openalex.org/S4210199683","display_name":"Frontiers in Drug Discovery","issn_l":"2674-0338","issn":["2674-0338"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Drug Discovery","raw_type":"journal-article"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7225823798.pdf","grobid_xml":"https://content.openalex.org/works/W7225823798.grobid-xml"},"referenced_works_count":57,"referenced_works":["https://openalex.org/W1191502296","https://openalex.org/W1608710587","https://openalex.org/W1965009739","https://openalex.org/W1968319881","https://openalex.org/W1968984443","https://openalex.org/W1970213932","https://openalex.org/W1976499671","https://openalex.org/W1988142400","https://openalex.org/W1998257649","https://openalex.org/W2007649418","https://openalex.org/W2009867031","https://openalex.org/W2011771098","https://openalex.org/W2017422910","https://openalex.org/W2028415754","https://openalex.org/W2029706756","https://openalex.org/W2030205108","https://openalex.org/W2043509228","https://openalex.org/W2049390023","https://openalex.org/W2049613194","https://openalex.org/W2054466658","https://openalex.org/W2054685187","https://openalex.org/W2058661551","https://openalex.org/W2073081213","https://openalex.org/W2083436457","https://openalex.org/W2090762415","https://openalex.org/W2095492902","https://openalex.org/W2095719702","https://openalex.org/W2096658459","https://openalex.org/W2104812730","https://openalex.org/W2108914190","https://openalex.org/W2121197248","https://openalex.org/W2132663758","https://openalex.org/W2133051701","https://openalex.org/W2152233061","https://openalex.org/W2160605524","https://openalex.org/W2208203352","https://openalex.org/W2328703221","https://openalex.org/W2330802164","https://openalex.org/W2336883206","https://openalex.org/W2404280981","https://openalex.org/W2519427975","https://openalex.org/W2546614309","https://openalex.org/W2593436234","https://openalex.org/W2615601352","https://openalex.org/W2774836366","https://openalex.org/W2797623003","https://openalex.org/W2899591074","https://openalex.org/W2901533885","https://openalex.org/W2911714350","https://openalex.org/W2965761847","https://openalex.org/W3011469361","https://openalex.org/W3033712668","https://openalex.org/W3056303605","https://openalex.org/W3086801715","https://openalex.org/W4313331609","https://openalex.org/W4388455891","https://openalex.org/W4416599143"],"related_works":[],"abstract_inverted_index":{"Src":[0,30,65,105,119,160,194],"kinase":[1],"and":[2,21,48,55,64,68,93,101,118,128,159,161,193],"epidermal":[3],"growth":[4],"factor":[5],"receptor":[6],"(EGFR)":[7],"are":[8],"important":[9],"mediators":[10],"of":[11,26],"oncogenic":[12],"signaling":[13],"pathways":[14],"involved":[15],"in":[16,157],"cellular":[17],"survival,":[18],"proliferation,":[19],"differentiation,":[20],"therapeutic":[22],"resistance.":[23],"The":[24,78,173],"activation":[25],"EGFR":[27,47,63,99,117,158,192],"can":[28],"stimulate":[29],"signaling,":[31],"which":[32],"contributes":[33],"to":[34,43,70],"resistance":[35],"against":[36,141],"EGFR-targeted":[37],"therapies.":[38],"Therefore,":[39],"this":[40],"study":[41],"aimed":[42],"identify":[44],"putative":[45,115,190],"dual":[46,116,191],"Src-binding":[49],"candidates":[50],"using":[51,90],"an":[52],"integrated":[53],"ligand-based":[54],"structure-based":[56],"computational":[57],"workflow.":[58],"Ligand-based":[59],"pharmacophore":[60,83],"models":[61],"for":[62,185],"were":[66,85,111],"constructed":[67],"used":[69],"screen":[71],"purchasable":[72],"compounds":[73,80,110],"from":[74,82],"the":[75,98,104,136,170],"ZINC":[76],"database.":[77],"hit":[79],"obtained":[81],"screening":[84],"refined":[86],"through":[87],"molecular":[88],"docking":[89],"iGEMDOCK":[91],"2.1":[92],"AutoDock4.2,":[94],"with":[95,154,169],"erlotinib":[96],"as":[97,103,114,180,188],"inhibitor":[100,106],"dasatinib":[102],"reference":[107,171],"drugs.":[108],"Six":[109],"computationally":[112],"prioritized":[113],"binders":[120],"based":[121],"on":[122],"their":[123],"binding-pose":[124],"persistence,":[125],"interaction":[126],"profiles,":[127],"comparative":[129],"MM/PBSA":[130],"energetics.":[131],"Among":[132],"them,":[133],"ZINC2770543":[134,149,177],"demonstrated":[135],"most":[137],"favorable":[138,163],"binding":[139,164],"profile":[140],"both":[142],"targets.":[143],"Molecular":[144],"dynamics":[145],"simulations":[146],"revealed":[147],"that":[148,176],"maintained":[150],"stable":[151],"hydrogen-bond":[152],"interactions":[153],"key":[155],"residues":[156],"exhibited":[162],"free":[165],"energy":[166],"values":[167],"compared":[168],"inhibitors.":[172],"findings":[174],"indicate":[175],"may":[178],"serve":[179],"a":[181,189],"potential":[182],"lead":[183],"compound":[184],"further":[186,197],"investigation":[187],"binder,":[195],"warranting":[196],"experimental":[198],"validation.":[199]},"counts_by_year":[],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2026-11-12T00:00:00"}